Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · 4

United Therapeutics Corporation

UTHRNASDAQEQUITYCurrent

SEC Filing

Filed Sep 3, 2026Accepted Sep 3, 2026, 4:31 PM EDTCIK 1082554Accession 0001106578-26-000134
Share

Company context

Founded by CEO Martine Rothblatt to discover a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics transforms the treatment of rare diseases and pioneers alternatives to expand the supply of transplantable organs. From our innovative therapies to our groundbreaking manufactured organs, we are bold and unconventional. We move quickly from scientific theory to practical technologies that can save lives. As a public benefit corporation, even our legal structure reflects our commitments. We serve patients, act with integrity, create long-term shareholder value, and operate with sustainable practices that protect the future we are working to build.

Current securities

Recent company filings

  1. 144 filingSep 17, 2026
  2. 4 filingSep 16, 2026
  3. 4 filingSep 14, 2026
  4. 144 filingSep 14, 2026
  5. Entry into a Material Definitive Agreement · Regulation FD DisclosureSep 8, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗